1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma.
Saved in:
| Title: | 1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma. |
|---|---|
| Authors: | Schadendorf, D.1 (AUTHOR), Dummer, R.2 (AUTHOR), Flaherty, K.T.3 (AUTHOR), Robert, C.4 (AUTHOR), Arance Fernandez, A.M.5 (AUTHOR), de Groot, J.W.6 (AUTHOR), Garbe, C.7 (AUTHOR), Gogas, H.8 (AUTHOR), Gutzmer, R.9 (AUTHOR), Krajsova, I.10 (AUTHOR), Liszkay, G.11 (AUTHOR), Loquai, C.12 (AUTHOR), Mandalà, M.13 (AUTHOR), Yamazaki, N.14 (AUTHOR), Guenzel, C.A.15 (AUTHOR), Polli, A.16 (AUTHOR), Thakur, M.17 (AUTHOR), di Pietro, A.18 (AUTHOR), Ascierto, P.A.19 (AUTHOR) |
| Source: | Annals of Oncology. 2023 Supplement 2, Vol. 34, pS670-S671. 2p. |
| Database: | Academic Search Ultimate |
| ISSN: | 09237534 |
|---|---|
| DOI: | 10.1016/j.annonc.2023.09.2247 |
